Trastuzumab, a monoclonal, anti-human ERBB2 protein antibody, inhibits tumor size and metastasis in vivo and in vitro through the upregulation of β-catenin and inhibition of SMAD3 [9]. The gene discussed is SMAD3; the disease is neoplasm.